Related Experiment Videos
p53 and MDM2 in the development and progression of bladder cancer
B J Schmitz-Dräger1, M Kushima, P Goebell
1Urologische Klinik, Heinrich-Heine-Universität, Düsseldorf, Deutschland.
Objective:
Earlier investigations have demonstrated that inactivation of the p53 tumor suppressor gene might play a role in the development and progression of bladder cancer. Complex formation with the MDM2 oncogene product is one mechanism inactivating the p53 protein. Therefore, the MDM2 and the p53 protein were investigated to study potential interactions in bladder cancer.
Method:
200 archival bladder tissue specimens from 92 patients were studied by immunohistochemistry using monoclonal antibodies DO-1 against p53 and IF2 against MDM2.
Results:
No staining was observed for p53 or MDM2 in normal urothelium. Alterations of both genes were rare in dysplasia. p53 accumulation was observed in 27-44% of the tumor stages examined. MDM2 overexpression increased from 18% in carcinoma in situ to 49% in T1 tumors, but was present in only 22% of the advanced tumors. Alterations of both genes were more frequent in high-grade lesions. To investigate the prognostic impact of these alterations 61 patients with superficial bladder tumors were followed for at least 2 years (mean 51 months). Multivariate analysis demonstrated that multifocal disease and p53 accumulation were significantly correlated with tumor progression (p = 0.0099 and 0.0135). MDM2 overexpression alone had no prognostic significance. Patients with alterations of both genes had a very high risk of tumor progression (p = 0.0064).
Conclusion:
These results demonstrate a positive correlation between p53 accumulation and MDM2 overexpression in the progression of bladder cancer which may have prognostic value.
Insights
p53 accumulation and MDM2 overexpression correlate with bladder cancer progression. Combined alterations indicate a high risk, suggesting prognostic value for these bladder cancer biomarkers.
Area of Science:
- Oncology
- Molecular Biology
- Uropathology
Background:
- The p53 tumor suppressor gene is frequently inactivated in bladder cancer.
- MDM2 oncogene product can inactivate p53 through complex formation.
- Understanding p53 and MDM2 interactions is crucial for bladder cancer research.
Purpose of the Study:
- To investigate the interaction between p53 and MDM2 proteins in bladder cancer.
- To evaluate the prognostic significance of p53 and MDM2 alterations in bladder cancer progression.
Main Methods:
- Immunohistochemistry was performed on 200 archival bladder tissue specimens.
- Monoclonal antibodies DO-1 (anti-p53) and IF2 (anti-MDM2) were utilized.
- 61 patients with superficial bladder tumors were followed for prognostic analysis.
Main Results:
- p53 accumulation was observed in 27-44% of tumors; MDM2 overexpression varied by stage (18%-49%).
- Alterations of both p53 and MDM2 were more frequent in high-grade bladder cancer.
- Multifocal disease and p53 accumulation correlated with tumor progression; combined alterations indicated high risk.
Conclusions:
- A positive correlation exists between p53 accumulation and MDM2 overexpression in bladder cancer progression.
- These molecular alterations may serve as valuable prognostic markers for bladder cancer.
- Further research into p53-MDM2 interactions could inform therapeutic strategies.